| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.15 | 6e-06 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.19 | 3e-05 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.19 | 0.0005 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.097 | 0.0006 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.0008 |